Patents by Inventor Alessandra D'Azzo
Alessandra D'Azzo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220406435Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: ApplicationFiled: August 18, 2022Publication date: December 22, 2022Applicant: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Publication number: 20200087704Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: ApplicationFiled: November 26, 2019Publication date: March 19, 2020Applicant: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Patent number: 10533208Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: GrantFiled: November 9, 2017Date of Patent: January 14, 2020Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Ida Annunziata, Alessandra D'Azzo
-
Publication number: 20180057854Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: ApplicationFiled: November 9, 2017Publication date: March 1, 2018Applicant: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Patent number: 9840727Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: GrantFiled: June 20, 2016Date of Patent: December 12, 2017Assignee: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Publication number: 20160304933Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: ApplicationFiled: June 20, 2016Publication date: October 20, 2016Applicant: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Patent number: 9399791Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: GrantFiled: August 28, 2012Date of Patent: July 26, 2016Assignee: St. Jude Children's Research HospitalInventors: Ida Annunziata, Alessandra D'Azzo
-
Publication number: 20140377245Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: ApplicationFiled: August 28, 2012Publication date: December 25, 2014Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Publication number: 20140193392Abstract: Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.Type: ApplicationFiled: August 28, 2012Publication date: July 10, 2014Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALInventors: Ida Annunziata, Alessandra D'Azzo, Shai White-Gilbertson
-
Patent number: 7425615Abstract: The present invention relates to a muscle-specific protein, Ozz, and nucleic acids encoding the protein, that regulates development and function of muscle cells. The invention further relates to muscle-specific regulated expression of the protein, and of heterologous genes under control of the same regulatory sequences. In a specific example, a murine Ozz protein of 285 amino acids is preferentially expressed by a 1.0 kb mRNA in heart and skeletal muscle. This protein shares significant homology with neuralized proteins, and associates with a number of muscle proteins, including ?-catenin.Type: GrantFiled: May 23, 2006Date of Patent: September 16, 2008Assignee: St. Jude Children's Research HospitalInventors: Alessandra D'azzo, Antonella Bongiovanni, Tommaso Nastasi
-
Patent number: 7241442Abstract: The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.Type: GrantFiled: December 11, 2003Date of Patent: July 10, 2007Assignee: St. Jude Children's Research HospitalInventors: Alessandra D'Azzo, Erik Jacobus Bonten
-
Patent number: 7232670Abstract: The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.Type: GrantFiled: September 28, 2001Date of Patent: June 19, 2007Assignee: St. Jude Children's Research HospitalInventors: Alessandra D'Azzo, Erik Jacobus Bonten
-
Publication number: 20060236410Abstract: The present invention relates to a muscle-specific protein, Ozz, and nucleic acids encoding the protein, that regulates development and function of muscle cells. The invention further relates to muscle-specific regulated expression of the protein, and of heterologous genes under control of the same regulatory sequences. In a specific example, a murine Ozz protein of 285 amino acids is preferentially expressed by a 1.0 kb mRNA in heart and skeletal muscle. This protein shares significant homology with neuralized proteins, and associates with a number of muscle proteins, including ?-catenin.Type: ApplicationFiled: May 23, 2006Publication date: October 19, 2006Applicant: St. Jude Children's Research HospitalInventors: Alessandra D'Azzo, Antonella Bongiovanni, Tommaso Nastasi
-
Patent number: 7074908Abstract: The present invention relates to a muscle-specific protein, Ozz, and nucleic acids encoding the protein, that regulates development and function of muscle cells. The invention further relates to muscle-specific regulated expression of the protein, and of heterologous genes under control of the same regulatory sequences. In a specific example, a murine Ozz protein of 285 amino acids is preferentially expressed by a 1.0 kb mRNA in heart and skeletal muscle. This protein shares significant homology with neuralized proteins, and associates with a number of muscle proteins, including ?-catenin.Type: GrantFiled: October 29, 2001Date of Patent: July 11, 2006Assignee: St. Jude Children's Research HospitalInventors: Alessandra D'Azzo, Antonella Bongiovanni, Tommaso Nastasi
-
Publication number: 20040126370Abstract: The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.Type: ApplicationFiled: December 11, 2003Publication date: July 1, 2004Applicant: St. Jude Children's Research Hospital, Inc.Inventors: Alessandra d'Azzo, Erik Jacobus Bonten
-
Publication number: 20020099173Abstract: The present invention relates to a muscle-specific protein, Ozz, and nucleic acids encoding the protein, that regulates development and function of muscle cells. The invention further relates to muscle-specific regulated expression of the protein, and of heterologous genes under control of the same regulatory sequences. In a specific example, a murine Ozz protein of 285 amino acids is preferentially expressed by a 1.0 kb mRNA in heart and skeletal muscle. This protein shares significant homology with neuralized proteins, and associates with a number of muscle proteins, including &bgr;-catenin.Type: ApplicationFiled: October 29, 2001Publication date: July 25, 2002Applicant: St. Jude Children's Research HospitalInventors: Alessandra D'Azzo, Antonella Bongiovanni, Tommaso Nastasi
-
Publication number: 20020077292Abstract: The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.Type: ApplicationFiled: September 28, 2001Publication date: June 20, 2002Inventors: Alessandra D'Azzo, Erik Jacobus Bonten